RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP(prostacyclin) receptor antagonists

被引:86
作者
Bley, KR [1 ]
Bhattacharya, A [1 ]
Daniels, DV [1 ]
Gever, J [1 ]
Jahangir, A [1 ]
O'Yang, C [1 ]
Smith, S [1 ]
Srinivasan, D [1 ]
Ford, APDW [1 ]
Jett, MF [1 ]
机构
[1] Roche Palo Alto, Palo Alto, CA 94304 USA
关键词
prostacyclin; PGI(2); prostanoid receptors; receptor binding; cAMP; pain; inflammation; cardiovascular system; pharmacokinetics;
D O I
10.1038/sj.bjp.0706554
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Prostacyclin (PGI(2)) possesses various physiological functions, including modulation of nociception, inflammation and cardiovascular activity. Elucidation of these functions has been hampered by the absence of selective IP receptor antagonists. 2 Two structurally distinct series of IP receptor antagonists have been developed: 4,5-dihydro-1H-imidazol-2-yl)-[4-(4-isopropoxy-benzyl)-phenyl]-amine (RO1138452) and R-3-(4-fluoro-phenyl)-2[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-propionic acid (RO3244794). 3 RO1138452and RO3244794 display high affinity for IP receptors. In human platelets, the receptor affinities (pK(i)) were 9.3 +/- 70.1 and 7.77 +/- 0.03, respectively; in a recombinant IP receptor system, pK(i) values were 8.77 +/- 0.06 and 6.97 +/- 0.1, respectively. 4 Functional antagonism of RO1138452and RO3244794 was studied by measuring inhibition of carbaprostacyclin-induced cAMP accumulation in CHO-K1 cells stably expressing the human IP receptor. The antagonist affinities (pK(i)) of RO1138452and RO3244794 were 9.07 +/- 0.06 and 8.57 +/- 0.11, respectively. 5 Selectivity profiles for RO1138452and RO3244794 were determined via a panel of receptor binding and enzyme assays. RO1138452 displayed affinity at I-2 (8.3) and PAF (7.9) receptors, while RO3244794 was highly selective for the IP receptor: pKi values for EP1 (< 5), EP3 (5.38), EP4 (5.74) and TP (5.09). 6 RO1138452(1-10 mg kg(-1), i.v.) and RO3244794 (1-30 mg kg(-1), i.v.) significantly reduced cetic acid-induced abdominal constrictions. RO1138452(3-100 mg kg(-1), p.o.) and RO3244794 (0.3-30 mg kg(-1), p.o.) significantly reduced carrageenan-induced mechanical hyperalgesia and edema formation. RO3244794 (1 and 10 mg kg(-1), p.o.) also significantly reduced chronic joint discomfort induced by monoiodoacetate. 7 These data suggest that RO1138452and RO3244794 are potent and selective antagonists for both human and rat IP receptors and that they possess analgesic and anti-inflammatory potential.
引用
收藏
页码:335 / 345
页数:11
相关论文
共 40 条
[1]   PRODUCTION OF PROSTACYCLIN IN MICE FOLLOWING INTRAPERITONEAL INJECTION OF ACETIC-ACID, PHENYLBENZOQUINONE AND ZYMOSAN - ITS ROLE IN THE WRITHING RESPONSE [J].
BERKENKOPF, JW ;
WEICHMAN, BM .
PROSTAGLANDINS, 1988, 36 (05) :693-709
[2]   The role of IP prostanoid receptors in inflammatory pain [J].
Bley, KR ;
Hunter, JC ;
Eglen, RM ;
Smith, JAM .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (04) :141-147
[3]   Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis [J].
Bove, SE ;
Calcaterra, SL ;
Brooker, RM ;
Huber, CM ;
Guzman, RE ;
Juneau, PL ;
Schrier, DJ ;
Kilgore, KS .
OSTEOARTHRITIS AND CARTILAGE, 2003, 11 (11) :821-830
[4]   ARTERIAL-WALLS GENERATE FROM PROSTAGLANDIN ENDOPEROXIDES A SUBSTANCE (PROSTAGLANDIN-X) WHICH RELAXES STRIPS OF MESENTERIC AND CELIAC ARTERIES AND INHIBITS PLATELET-AGGREGATION [J].
BUNTING, S ;
GRYGLEWSKI, R ;
MONCADA, S ;
VANE, JR .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 1976, 12 (06) :897-913
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]   Role of prostacyclin in the cardiovascular response to thromboxane A2 [J].
Cheng, Y ;
Austin, SC ;
Rocca, B ;
Koller, BH ;
Coffman, TM ;
Grosser, T ;
Lawson, JA ;
FitzGerald, GA .
SCIENCE, 2002, 296 (5567) :539-541
[7]   Discovery and SAR development of 2-(phenylamino) imidazolines as postacyclin receptor antagonists [J].
Clark, RD ;
Jahangir, A ;
Severance, D ;
Salazar, R ;
Chang, T ;
Chang, D ;
Jett, MF ;
Smith, S ;
Bley, K .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (04) :1053-1056
[8]  
COLEMAN RA, 1994, PHARMACOL REV, V46, P205
[9]  
COURNOYER RLK, 2001, Patent No. 0168591
[10]   Central nociceptive role of prostacyclin (IP) receptor induced by peripheral inflammation [J].
Doi, Y ;
Minami, T ;
Nishizawa, M ;
Mabuchi, T ;
Mori, H ;
Ito, S .
NEUROREPORT, 2002, 13 (01) :93-96